Literature DB >> 2461595

The role of biological response modifiers in metastatic renal cell carcinoma.

H B Muss1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2461595

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  9 in total

1.  Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study.

Authors:  J P Kuebler; P J Goodman; T D Brown; E D Crawford; C L Reitz; W A Knight; J A Kish
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

Review 2.  Tumors of the kidney, ureter, and bladder.

Authors:  W A See; R D Williams
Journal:  West J Med       Date:  1992-05

3.  Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.

Authors:  J T Donaldson; T E Keane; S H Poulton; P J Walther
Journal:  Urol Res       Date:  1990

4.  Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial.

Authors:  R T Zon; J McClean; D Helman; R Ansari; J Picus; A Sandler; S D Williams; P J Loehrer
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

5.  Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.

Authors:  S Küpeli; M Beksac; B Küpeli; S Baltaci; O Süzer
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

6.  Significance of angiogenesis and microvascular invasion in renal cell carcinoma.

Authors:  Yoram Dekel; Rumelia Koren; Valentina Kugel; Pinhas M Livne; Rivka Gal
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

7.  Ifosfamide, vindesine and recombinant alpha-interferon combination chemotherapy for metastatic renal cell carcinoma.

Authors:  H J König; W Gutmann; J Weissmüller
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

8.  Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial.

Authors:  R S Witte; P Elson; G T Bryan; D L Trump
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

9.  CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.

Authors:  P J Adam; J A Terrett; G Steers; L Stockwin; J A Loader; G C Fletcher; L-S Lu; B I Leach; S Mason; A C Stamps; R S Boyd; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2006-08-07       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.